Novartis (NVS) has obtained a temporary order from the US Court of Appeals for the Federal Circuit, preventing MSN Pharmaceuticals from launching a generic version of its heart-failure drug, Entresto, according to the court order on Thursday.
MSN Pharmaceuticals had planned to launch its generic on Thursday, coinciding with the expiration of Novartis' patent, Reuters reported late Thursday.
The court said it decision would allow time to consider Novartis' request for a longer ban on the generic release.
The decision comes after the Federal Circuit last week overturned a 2023 ruling that invalidated one of Novartis' patents, which the company argued protects its exclusive rights to Entresto until July.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.